Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Tag: DBV Technologies
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...
Dave Bloom
-
2021/01/08
The company announced they would be laying off 200 employees in Q1.
Viaskin Peanut “Patch” Therapy Takes Next Step Toward Approval… in Europe
Dave Bloom
-
2020/11/03
The Marketing Authorization Application for Viaskin™ Peanut was validated by the European Medicines Agency.
FDA Denies Approval of Viaskin Peanut “Patch” Therapy
Dave Bloom
-
2020/08/04
The FDA raised concerns that adhesion of the patch would affect the efficacy of the therapy.
Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon?...
Dave Bloom
-
2020/06/30
Company is restructuring in anticipation of delays.
FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...
Dave Bloom
-
2020/03/17
The company warned the FDA's target date for their decision on approval could be delayed.
FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...
News Wire ~ 3rd Party Press Release
-
2020/02/22
Next step in the approval process for the therapy scheduled for May 15, 2020.
DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...
News Wire ~ 3rd Party Press Release
-
2020/01/09
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/10/04
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy
Dave Bloom
-
2019/09/15
What it is, what it treats, who it is for, how it is used, et al.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/08/08
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
1
2
3
4
Page 1 of 4